X
KEY PRODUCTS
Details:
Ranivisio (ranibizumab) is a VEGF-A inhibitor, which is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Ranivisio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
The aim of the partnership is the contract development of a Single Pill, Biramlo, with a combination of two leading active ingredients,bisoprolol fumarate and amlodipine for the treatment of high blood pressure (hypertension).
Lead Product(s): Bisoprolol Fumarate,Amlodipine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Biramlo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Apontis Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 19, 2022
Details:
The active substance of Ranivisio is ranibizumab, a monoclonal antibody fragment (ATC code: S01LA04) which modulates angiogenesis by inhibiting vascular endothelial growth factor A. Ranivisio is a biosimilar medicinal product.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Ranivisio
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hypertension).
Lead Product(s): Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Apontis Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 14, 2021
Details:
Vorient-Generic (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma & advanced soft tissue sarcoma who have received prior chemotherapy.
Lead Product(s): Pazopanib Hydrochloride
Therapeutic Area: Oncology Product Name: Vorient-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Pharmacare Premium
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2021
Details:
Corifarma and Midas entered into an exclusive out-licensing cooperation for the European territory. The respective product, Raltegravir, can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.
Lead Product(s): Raltegravir Potassium
Therapeutic Area: Infections and Infectious Diseases Product Name: Raltegravir-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Coripharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
